CapsoVision, Inc centers its business on ingestible capsule endoscopy solutions enhanced with proprietary 360° panoramic imaging and emerging AI technologies. Their flagship product, CapsoCam Plus, continues to grow sales with FDA clearance in place, while the next-generation CapsoCam Colon capsule is progressing through pivotal clinical trials aiming for a mid-2027 market entry. The firm’s operating losses persist amid substantial R&D investments and commercialization efforts, heightening reliance on external financing. Supply chain concentration in Asia and regulatory risks remain material constraints. Success depends on timely regulatory approvals, scaling revenue beyond small bowel diagnostics, and effective cash management.